On October 3, 2025 Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, reported two upcoming presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting, taking place in National Harbor, Md., Nov. 5-9, 2025 (Press release, Dispatch Bio, OCT 3, 2025, View Source [SID1234656429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors
Abstract: 393
Primary Category: Cellular Therapies
Poster Presentation Day: Friday, Nov. 7
Presenter: Lisa Cucolo, Ph.D., Senior Scientist at Dispatch

Title: Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment
Abstract: 394
Primary Category: Cellular Therapies
Poster Presentation Day: Saturday, Nov. 8
Presenter: Raymond Liu, Ph.D., Co-Founder and Head of Synthetic Biology at Dispatch